54057-46-4

Basic information

• Product Name: 4-[(4-fluorobenzoyl)amino]benzoic acid
• Synonyms: benzoic acid, 4-[(4-fluorobenzoyl)amino]-
• CAS NO: 54057-46-4
• Molecular Formula: C₁₄H₁₀FNO₃
• Molecular Weight: 259.2325
• Mol File: 54057-46-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 360.2°C at 760 mmHg
• Flash Point: 171.7°C
• Density: 1.4g/cm³
• Vapor Pressure: 8.1E-06mmHg at 25°C
• Refractive Index: 1.653
• CAS DataBase Reference: 4-[(4-fluorobenzoyl)amino]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-fluorobenzoyl)amino]benzoic acid(54057-46-4)
• EPA Substance Registry System: 4-[(4-fluorobenzoyl)amino]benzoic acid(54057-46-4)

Safety Data

• Hazardous Substances Data: 54057-46-4(Hazardous Substances Data)

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 150-13-0 4-amino-benzoic acid 
• 172950-63-9 ethyl 4-(4-fluorobenzamido)benzoate 
• 456-22-4 4-Fluorobenzoic acid 
• 94-09-7 p-aminoethylbenzoate 
• 459-57-4 4-fluorobenzaldehyde 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 735351-37-8 4-(4-fluoro-benzoylamino)benzoyl chloride 
• 1258550-47-8 4-fluoro-N-(4-(3-nitro-4-(2-(phenylthio)ethylamino)phenylsulfonylcarbamoyl)phenyl)benzamide 
• 1369424-04-3 C₂₃H₁₇FN₄O₄S₂ 

Relevant articles and documents

Synthetic and Biological Studies on New Urea and Triazole Containing Cystobactamid Derivatives

Cystobactamids belong to the group of arene-based oligoamides that effectively inhibit bacterial type IIa topoisomerases. Cystobactamid 861-2 is the most active member of these antibiotics. Most amide bonds present in the cystobactamids link benzoic acids

Thermoplastic polymer composition

The invention provides a compound conforming to the structure of Formula (C) The invention also provides a thermoplastic polymer composition comprising a polyolefin polymer and a compound conforming to the structure of Formula (C) as a nucleating agent.

Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors

Fifteen novel sulfathiazole-related compounds were designed as PTP1B inhibitors based on a previously reported allosteric inhibitor (1) of PTP1B. These compounds were synthesized and evaluated against human recombinant PTP1B. Six compounds (3, 4, 8 and 14